1. CSF tau proteins correlate with an atypical clinical presentation in dementia with Lewy bodies
- Author
-
Di Censo, R., Abdelnour, C., Blanc, F., Bousiges, O., Lemstra, A. W., Van Steenoven, I., Onofrj, M., Aarsland, D., Collaborators: Angelo Antonini, Bonanni L., Clive, Ballard, Claudio, Babiloni, Alexandra, Bernadotte, Roberta, Biundo, Bradly, Boeve, Jan, Booij, Sevasti, Bostantjopoulou, Carlo De Lena, Richard, Dodel, Cristian, Falup-Pecurariu, Tormod, Fladby, Sara Garcia- Pacek, Josep, Garre, Geurtsen, Gert J., Martha Therese Gjestsen, Oskar, Hansson, Frank Jan de Jong, Vesna, Jelic, Zoe, Katsarou, Milica, Kramberger, Elisabet, Londos, Ian, Mckeith, Brit, Mollenhauer, Nobili, FLAVIO MARIANO, John, O’Brien, Alessandro, Padovani, Maria, Petrova, Andrea, Pilotto, Irena, Rektorova, Arvid, Rongve, Jon, Snaedal, Elka, Stefanova, Per, Svenningsson, John Paul Taylor, Pietro, Tiraboschi, Latchezar, Traykov, Rik, Vandenberghe, Zuzana, Walker, Eric, Westman, Bengt, Winblad, Henrik, Zetterberg., Laboratoire des sciences de l'ingénieur, de l'informatique et de l'imagerie (ICube), Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS)-École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Réseau nanophotonique et optique, Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Matériaux et nanosciences d'Alsace (FMNGE), Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Institut de Chimie du CNRS (INC)-Université de Strasbourg (UNISTRA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Laboratoire de neurosciences cognitives et adaptatives (LNCA), Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), European DLB consortium, Neurology, Amsterdam Neuroscience - Neurodegeneration, Laboratory Medicine, Radiology and nuclear medicine, École Nationale du Génie de l'Eau et de l'Environnement de Strasbourg (ENGEES)-Université de Strasbourg (UNISTRA)-Institut National des Sciences Appliquées - Strasbourg (INSA Strasbourg), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut National de Recherche en Informatique et en Automatique (Inria)-Les Hôpitaux Universitaires de Strasbourg (HUS)-Centre National de la Recherche Scientifique (CNRS)-Matériaux et Nanosciences Grand-Est (MNGE), Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Réseau nanophotonique et optique, Université de Strasbourg (UNISTRA)-Université de Haute-Alsace (UHA) Mulhouse - Colmar (Université de Haute-Alsace (UHA))-Centre National de la Recherche Scientifique (CNRS)-Université de Strasbourg (UNISTRA)-Centre National de la Recherche Scientifique (CNRS), ANS - Neurodegeneration, AMS - Restoration & Development, Medical Psychology, Radiology and Nuclear Medicine, and APH - Mental Health
- Subjects
Lewy Body Disease ,Male ,medicine.medical_specialty ,Physical examination ,CSF ,Lewy body dementia ,tau ,tau Proteins ,Disease ,Aged ,Biomarkers ,Female ,Humans ,Retrospective Studies ,03 medical and health sciences ,0302 clinical medicine ,Cerebrospinal fluid ,Sciences cognitives/Neurosciences ,Internal medicine ,mental disorders ,medicine ,Dopamine transporter ,medicine.diagnostic_test ,biology ,business.industry ,Dementia with Lewy bodies ,[SCCO.NEUR]Cognitive science/Neuroscience ,Retrospective cohort study ,medicine.disease ,3. Good health ,Psychiatry and Mental health ,Clinical diagnosis ,Cochran–Armitage test for trend ,biology.protein ,Surgery ,Neurology (clinical) ,business ,030217 neurology & neurosurgery - Abstract
A cerebrospinal fluid (CSF) Alzheimer’s disease (AD) profile, that is, decreased amyloid-β1-42 (Aβ42) and increased total tau protein (t-tau) and/or phosphorylated tau at threonine-181 (p-tau),1 has been identified in a substantial number of dementia with Lewy bodies (DLB) patients, and it has been related to a more rapid cognitive decline.1 We investigated the association between AD CSF biomarkers and DLB core clinical features to better understand in vivo how AD pathology influences DLB clinical presentation. We included 171 subjects with a clinical diagnosis of probable DLB2 3 from the European DLB consortium (E-DLB). The centres involved are summarised in online supplementary table 1. Clinical examination was performed as previously reported.1 Dopamine transporter (DAT) single-photon emission CT scans (123I-FP-CIT-SPECT) were performed in 80 patients.### Supplementary data [jnnp-2019-320980supp001.pdf] CSF samples were collected at each centre according to the procedures detailed in online supplementary table 1. An AD CSF profile was defined as low Aβ42 combined with high t-tau or p-tau.1 Information about pharmacological treatments of patients were not available at each centre. Statistical analyses were performed using SPSS V.24. Association between CSF biomarkers (normal or abnormal), and each core features (present or absent), were tested with χ2 test. Associations between single CSF biomarkers and groups of subjects with different core clinical features’ number (1–4) were tested with Armitage test for trend. Local ethics committees approved the study. All patients gave their written consent for the use of their …
- Published
- 2020
- Full Text
- View/download PDF